Ribavirin enhances interferon-gamma levels in patients with chronic hepatitis C treated with interferon-alpha

Area of Science:

• Immunology
• Hepatology
• Virology

Background:

• Chronic hepatitis C (HCV) treatment with interferon (IFN)-alpha shows variable efficacy.
• Combining IFN-alpha with ribavirin improves treatment outcomes, but the underlying mechanisms are not fully understood.

Purpose of the Study:

• To investigate the impact of IFN-alpha monotherapy versus combination therapy with ribavirin on immune responses in chronic hepatitis C patients.
• To elucidate the immunological mechanisms behind the enhanced efficacy of combination therapy.

Main Methods:

• Studied 51 chronic hepatitis C patients undergoing treatment.
• Assessed hepatitis C core antigen-specific proliferative responses, cytokine production (IFN-gamma), natural killer (NK) cell cytotoxicity, and cytotoxic T cell activity.
• Compared immune parameters between monotherapy and combination therapy groups, and between responders and non-responders.

Main Results:

• Combination therapy led to higher rates of viral clearance and biochemical normalization.
• Natural killer (NK) cell function and IFN-gamma production increased in responders, particularly in the combination therapy group.
• Core antigen-specific proliferative responses decreased post-treatment, while cytotoxic T cell activity increased significantly in responders receiving combination therapy.

Conclusions:

• Enhanced immune responses, particularly type-1 T helper cell activity, contribute to the improved efficacy of combining ribavirin with IFN-alpha for chronic hepatitis C.
• The study highlights the immunomodulatory effects of combination therapy in chronic HCV infection.